RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

Clinical trials for RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) explained in plain language.

Never miss a new study

Get alerted when new RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) trials appear

Sign up with your email to follow new studies for RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

CAR-T therapy trial offers new hope for Tough-to-Treat lymphoma

Disease control Completed

This study tested whether a personalized immune cell therapy (called axicabtagene ciloleucel or CAR-T) works better than standard second-line treatments for patients with a fast-growing type of lymphoma that has returned or not responded to initial chemotherapy. It involved 359 a…

Matched conditions: RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

Phase: PHASE3 • Sponsor: Kite, A Gilead Company • Aim: Disease control

Last updated Mar 27, 2026 12:38 UTC

RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

Get alerted when new RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) trials appear

CAR-T therapy trial offers new hope for Tough-to-Treat lymphoma